Cite
HARVARD Citation
Guérard, N. et al. (2018). Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement. Clinical pharmacology & therapeutics. 103 (4), pp. 703-711. [Online].